ArticleNeuroimage. Reports2026
Reduced alpha power predicts recurrence risk in major depressive disorder.
Article in Neuroimage. Reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A high proportion of individuals with major depressive disorder (MDD) develop recurrent episodes. A better understanding and the identification of markers of recurrence risk are needed to develop prophylactic treatments and to support treatment decisions. Electroencephalography (EEG) is a scalable approach to identifying potential markers. Alpha band (8-13Hz) power and frontal alpha asymmetry (FAA) have been implicated in the pathophysiology of depression, however prospective studies of recurrence risk are sparse. Here, we investigated frontal alpha power and FAA in remitted MDD patients, to assess their potential as predictors of future depressive episodes. Methods: In total, 84 participants (n = 53 medication-free remitted MDD, n = 31 control participants with no family history of MDD) completed resting EEG testing. Remitted MDD patients were followed up clinically to determine recurrence over 14 months. Resting frontal alpha power and FAA were compared between groups (controls, stable remission, subclinical symptoms, recurrent episode) and binary logistic regression models were used to predict recurrence risk in remitted MDD patients. Results: Patients who developed a recurring episode showed reduced frontal alpha power at baseline compared to controls and patients who remained in stable remission. No group effect was found for FAA. When combining clinical predictors with frontal alpha power, prediction accuracy for recurring episodes was 88%. Conclusions: This study demonstrates that reduced frontal alpha power has the potential to be further developed as a marker for recurrence risk in MDD, and could contribute to recurrence risk prediction models. This calls for larger studies using cross-validated prediction modelling techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.